Results 131 to 140 of about 854 (146)

Pharmacokinetic and pharmacodynamic considerations with psychiatric disorders and migraines. [PDF]

Ment Health Clin
Palmer EC, Shuman MD, Oiler IG.
europepmc   +1 more source

Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Lasmiditan for Acute Treatment of Migraine.

Brain, 2019
Lasmiditan, a serotonin 5-HT1F receptor agonist, was effective for acute treatment of patients with migraine in a phase 3 double-blind randomized controlled study.
Charly Gaul, Ellen B Dennehy
exaly   +2 more sources

Lasmiditan for the Acute Treatment of Migraine: Subgroup Analyses by Prior Response to Triptans [PDF]

Cephalalgia, 2020
BACKGROUND: Lasmiditan demonstrated superiority to placebo in the acute treatment of migraine in adults with moderate/severe migraine disability in two similarly designed Phase 3 trials, SAMURAI and SPARTAN.
Li Shen Loo, Joshua Tobin, Mika Komori
exaly   +2 more sources

Lasmiditan for the Treatment of Migraine

Expert Opinion on Investigational Drugs, 2017
Migraine is one of the most common diseases in the world, with high economical and subjective burden. Migraine acute therapy is nowadays based on specific and non-specific drugs but up to 40% of episodic migraineurs still have unmet treatment needs and ...
Giovanna Gentile, Luana Lionetto, Martina Curto   +2 more
exaly   +2 more sources

Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies [PDF]

Headache, 2019
OBJECTIVE: To expand on available information on the efficacy of oral lasmiditan for the acute treatment of migraine with particular focus on the timing of the effect and on its impact on migraine-associated symptoms.
Messoud Ashina, Cristina Tassorelli, Kraig S Kinchen   +2 more
exaly   +2 more sources

Randomized, Controlled Trial of Lasmiditan Over Four Migraine Attacks: Findings From the CENTURION Study

Cephalalgia, 2021
Background: We present findings from the multicenter, double-blind Phase 3 study, CENTURION. This study was designed to assess the efficacy of and consistency of response to lasmiditan in the acute treatment of migraine across four attacks.
Uwe Reuter, Messoud Ashina, John H Krege
exaly   +2 more sources

Efficacy and Tolerability of Lasmiditan, an Oral 5-HT1F Receptor Agonist, for the Acute Treatment of Migraine: A Phase 2 Randomised, Placebo-Controlled, Parallel-Group, Dose-Ranging Study

Lancet Neurology, The, 2012
peer reviewedBACKGROUND: Lasmiditan (COL-144) is a novel, centrally acting, highly selective 5-HT(1F) receptor agonist without vasoconstrictor activity that seemed effective when given as an intravenous infusion in a proof-of-concept migraine study.
Jean Schoenen, Uwe Reuter
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Phase 2 Randomized Placebo-Controlled Study of Lasmiditan for the Acute Treatment of Migraine in Japanese Patients

Headache, 2021
Fumihiko Sakai, Gosuke Homma, Takao Takeshima   +2 more
exaly  

Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo- and Alprazolam-Controlled Crossover Study

Journal of Clinical Pharmacology, 2020
Paul H Berg, Li Shen Loo
exaly  

Effect of a Change in Lasmiditan Dose on Efficacy and Safety in Patients With Migraine

Postgraduate Medicine, 2021
Jessica Ailani, Mario Fernando Prieto Peres, Paula Hauck   +2 more
exaly